Guido Stubbe

BE Angels SA is an independent private equity firm with its headquarters in Louvain-la-Neuve, Belgium. It was founded in 1999.

Nausicaa Ventures is an independent venture capital firm founded in 2009 by Michel Helbig de Balzac & Maurice Olivier. The firm is headquartered in Walloon Region, Belgium.

Nomadesk NV develops cloud-based enterprise file sharing and synchronization technology solutions. The firm develops cloud software for sharing and synchronizing electronic documents, allowing foremost business users to open, share, synchronize and secure files from anywhere-online and offline. The company was founded by Filip Tack, Peter Geldhof and Miguel de Buf in 2004 and is headquartered in Sint-Martens-Latem, Belgium.

SmartFin is a venture capital firm founded in 2014 by Jürgen Ingels and Bart Luyten. The firm headquartered at Belgium.

Vimavi NV is a private company based in Sint-Martens-Latem, Belgium. Dimitri Vermeersch has been the CEO of the Belgian company since 2011.

Betty Blocks BV is a web-based platform. It develops web applications. The company was founded in 2012 and is headquartered in Alkmaar, The Netherlands.

Eyesee NV engages in behavioral market research. It offers advertising, digital, and shopper insights and innovation and strategy solutions. The company was founded in 2013 and is headquartered in Ghent, Belgium.

ING Belgium NV (Private Equity) is a Private Equity/Venture Capital firm, a subsidiary of ING Bank NV, Amsterdam, succursale de Lancy/Genève founded in 1997. ING Belgium NV (Private Equity) is headquartered in Grünwald.

Garage Bruyninx NV operates car dealerships. The firm offers Fiat and Lancia cars. The company is headquartered in Hasselt, Belgium.

Mediahuis Partners NV provides media solutions. It prints news, and operates radio and television networks. Its brands include Mediahuis, Gazet van Antwerpen, Het Belang van Limburg, De Standaard, Het Nieuwsblad de Gentenaar, Rondom, Corelio printing, Coldset Printing Partners, Vier, Vijf, Woestijnvis, Nostalgie, Rob TV, and Gezondheid.be. The company was founded on June 29, 1976 and is headquartered in Groot-Bijgaarden, Belgium.

Vitalo Industries excels in design, production, sub-assembly of interior and exterior components for industrial vehicles, equipment and acoustic applications. You are kindly invited to browse through its selection of industrial applications. Feel free to contact Vitalo regarding any request you may have. To ensure its continuous, worldwide growth and leading position Vitalo Industries calls on your talent and dedication, with career opportunities matching your ambition.

ING Corporate Investments focuses on small & medium-sized companies with a turnover of between €5 - €100 million located in Belgium or France. It invest in sectors such as manufacturing, engineering, logistics, distribution, services, information technologies, software, and telecommunications. It provides investments between €2 - €20 million in equity and can invest in convertible notes for MBOs or MBIs, growth, and later-stage venture capital. The fund can act as a lead investor and has an exit horizon of 4 to 6 years.

Fedrus International NV operates as a holding company with interests in roofing and façade materials. The company was founded on May 21, 2015 and is headquartered in Puurs, Belgium.

Sogam SA is an investment holding Belgian company founded in 1964. The private company is based in Brussels, Belgium. Sogam functions as an investment holding company.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.

The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium.

Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium.